FHTX Foghorn Therapeutics Inc
Price (delayed)
$9.76
Market cap
$540.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.95
Enterprise value
$440.27M
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The
Highlights
The equity has soared by 85% from the previous quarter and by 71% YoY
The company's revenue has surged by 62% YoY and by 3.8% QoQ
Key stats
What are the main financial stats of FHTX
Market
Valuations
Earnings
Shares outstanding
55.33M
Market cap
$540.01M
Enterprise value
$440.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
14.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.51
Revenue
$35.19M
EBIT
-$83.72M
EBITDA
-$74.79M
Free cash flow
-$109.87M
Per share
Balance sheet
Liquidity
EPS
-$1.95
Free cash flow per share
-$2.13
Book value per share
-$0.34
Revenue per share
$0.68
TBVPS
$6.37
Total assets
$328.59M
Total liabilities
$342.91M
Debt
$40.92M
Equity
-$14.32M
Working capital
$238.75M
Debt to equity
-2.86
Current ratio
5.69
Quick ratio
5.64
Net debt/EBITDA
1.33
Margins
Efficiency
Dividend
EBITDA margin
-212.6%
Gross margin
100%
Net margin
-245.7%
Operating margin
-276.7%
Return on assets
-29.2%
Return on equity
N/A
Return on invested capital
-43.5%
Return on capital employed
-30.1%
Return on sales
-237.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FHTX stock price
How has the Foghorn Therapeutics stock price performed over time
Intraday
-0.81%
1 week
5.29%
1 month
55.91%
1 year
60.79%
YTD
51.32%
QTD
69.74%
Financial performance
How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$35.19M
Gross profit
$35.19M
Operating income
-$97.37M
Net income
-$86.45M
Gross margin
100%
Net margin
-245.7%
The company's revenue has surged by 62% YoY and by 3.8% QoQ
FHTX's gross profit has surged by 62% year-on-year and by 3.8% since the previous quarter
The company's net margin has surged by 53% YoY and by 10% QoQ
FHTX's operating margin has soared by 52% YoY and by 9% QoQ
Growth
What is Foghorn Therapeutics's growth rate over time
Valuation
What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
14.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.51
Foghorn Therapeutics's EPS has increased by 29% YoY and by 11% from the previous quarter
The equity has soared by 85% from the previous quarter and by 71% YoY
FHTX's P/S is 85% higher than its last 4 quarters average of 7.8
The company's revenue has surged by 62% YoY and by 3.8% QoQ
Efficiency
How efficient is Foghorn Therapeutics business performance
Foghorn Therapeutics's ROS has soared by 54% YoY and by 10% from the previous quarter
FHTX's return on invested capital is down by 23% year-on-year and by 5% since the previous quarter
The ROA has grown by 6% from the previous quarter
Dividends
What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FHTX.
Financial health
How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 4.2% lower than its total liabilities
FHTX's quick ratio is up by 41% since the previous quarter and by 12% year-on-year
The current ratio has grown by 40% from the previous quarter and by 11% YoY
The debt to equity has shrunk by 195% YoY
The equity has soared by 85% from the previous quarter and by 71% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.